CRB-913 + Placebo
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Obese But Otherwise Healthy Participants
Conditions
Obese But Otherwise Healthy Participants
Trial Timeline
Dec 4, 2025 → Jul 31, 2026
NCT ID
NCT07310901About CRB-913 + Placebo
CRB-913 + Placebo is a phase 1 stage product being developed by Corbus Pharmaceuticals for Obese But Otherwise Healthy Participants. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07310901. Target conditions include Obese But Otherwise Healthy Participants.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07310901 | Phase 1 | Recruiting |
Competing Products
9 competing products in Obese But Otherwise Healthy Participants
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lorcaserin | Eisai | Phase 1 | 33 |
| Bardoxolone methyl + Placebo | Kyowa Kirin | Phase 1 | 33 |
| LIK066 + Placebo | Novartis | Phase 2 | 52 |
| Investigational new drug company code: BGS649 + Placebo | Novartis | Phase 2 | 52 |
| Placebo + CT-388 | Roche | Phase 2 | 52 |
| Growth hormone treatment | Pfizer | Pre-clinical | 22 |
| BMS-963272 + Placebo | Bristol Myers Squibb | Phase 1 | 32 |
| ALN-4324 + Placebo | Alnylam Pharmaceuticals | Phase 1/2 | 38 |
| Aleniglipron + Placebo | Structure Therapeutics | Phase 2 | 47 |